House to mark up bill targeting Chinese biotech and genomics companies
The House Oversight Committee will mark up a far-reaching bill on May 15 that, if passed, could force many US biopharma companies to cut ties with WuXi and several other Chinese life sciences...
View ArticleClik here to view.
AbbVie puts $161M into new R&D site in Germany, will add 300 jobs
AbbVie is investing around €150 million ($161 million) into an R&D site at its Rhineland-Palatinate location in Germany which it expects to complete in 2027, the company announced this week. At a...
View ArticleClik here to view.
Senators from both parties introduce menopause research bill
A group of Democratic and Republican senators introduced a bill on Thursday that calls for $275 million toward federal menopause research and awareness efforts over five years. The legislation would...
View ArticleJ&J showcases more bladder cancer results from 'pretzel' drug-device combo
Updated data from a trial of Johnson & Johnson’s experimental “pretzel” showed that more than 80% of bladder cancer patients who got the treatment saw their tumors melt away, building on a readout...
View ArticleNovartis’ radiopharma gambit; Weight loss battle plays out; Spark...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleGossamer Bio collaborates with Chiesi to develop, commercialize seralutinib
Gossamer Bio has lined up a partner to foot the development and commercialization bill for its make-or-break late-stage drug, expanding Phase 3 plans and paving the way for its launch outside the US....
View ArticleClik here to view.
AstraZeneca-allied Eccogene targets early 2025 Nasdaq IPO with multiple NASH...
Eccogene, a Boston and Shanghai biotech working on an oral GLP-1 candidate with AstraZeneca, is considering an initial public offering early next year, CEO Jingye Zhou told Endpoints News. Jingye Zhou...
View ArticleGates, Novo Nordisk, Wellcome foundations put $300M in global health;...
Plus, news about EyePoint, Lyra Therapeutics and Plus Therapeutics: For global health, $300 million: The Bill & Melinda Gates Foundation, the Novo Nordisk Foundation and Wellcome are each pitching...
View ArticleJ&J reports latest data on Balversa-based ‘pretzel’ therapy for bladder cancer
Bladder cancer patients with a common mutation saw promising early results after receiving a Johnson & Johnson targeted therapy that administers the drug sold as Balversa through a slow-releasing...
View ArticleRemodeling REMS: FDA kicks off guidance series with draft on new framework
In the first of what’s expected to be a series of REMS-related advice for the industry, the FDA on Monday unveiled new draft guidance on how to improve the safety programs often attached to higher-risk...
View ArticleADC Therapeutics reveals topline Zynlonta data, $105M stock offering
ADC Therapeutics announced a $105 million offering after sharing what it called positive topline data from a Phase 2 trial of its cancer drug Zynlonta. The Swiss biotech is selling off 13.4 million...
View ArticleClik here to view.
Industry groups critique new guidance for Medicare drug price negotiations in...
The Centers for Medicare & Medicaid Services proposed a number of changes to its Medicare negotiation guidance on Friday, some of which would affect how the next round of drug prices is negotiated...
View ArticleSen. Cassidy calls on Biden to do better at sharing H5N1 bird flu information
Senate HELP Committee ranking member Bill Cassidy (R-LA) is calling on the Biden administration to do a better job of communicating its findings on the recent outbreak of avian flu among cattle that...
View ArticleUPenn and Stanford analysis finds no secondary cancer cases directly due to...
The University of Pennsylvania’s pioneering cell therapy physician Carl June shared new data Monday that showed the risk of secondary cancers following CAR-T therapy was very low. In over 1,500...
View ArticleIllumina takes a step toward spinning off Grail, though keeps option open for...
Illumina prefers to spin off Grail into an independent business rather than sell the cancer diagnostics company, according to a financial document released Monday that describes the Illumina board’s...
View ArticleClik here to view.
Vertex touts Casgevy sickle cell launch as bluebird makes progress with rival...
Vertex said it’s making strong progress bringing its CRISPR Therapeutics-partnered gene therapy to patients after a landmark approval for sickle cell disease in December. Chief operating officer Stuart...
View ArticleMemo Therapeutics completes $49M Series C to develop kidney transplant...
Swiss biotech Memo Therapeutics raised $22 million (CHF 20 million) in a Series C extension to develop an antibody treatment for BK polyomavirus (BKV) infection in kidney transplant recipients, a...
View ArticleFlagship commits $50M to new startup that scours viral proteins for new drugs
In the midst of the Covid-19 pandemic, while most scientists were busy plotting new ways to combat viruses, one startup quietly began a counterintuitive campaign: getting viruses to work for us,...
View ArticleZenas BioPharma closes $200M round to broaden autoimmune potential for lead drug
Lonnie Moulder’s latest biotech has secured some new cash to expand its work in autoimmune diseases. The startup, Zenas BioPharma, closed a $200 million Series C and will use the money to fund clinical...
View ArticleClik here to view.
Arbor acquires Feng Zhang startup for next-gen gene editing enzymes
In the bid to lock up patent rights to a growing suite of gene editing technologies, Arbor Biotechnologies has acquired a small startup founded by MIT scientist and CRISPR pioneer Feng Zhang, the...
View Article